8-K: Moderna Appoints David Rubenstein to Board, Two Directors Retire

Moderna has appointed David M. Rubenstein to its Board of Directors, effective August 5, 2024, while Robert Langer and Stephen Berenson will retire from the board on the same date.

Summary

• Moderna announced the appointment of David M. Rubenstein to its Board of Directors, effective August 5, 2024.
• Robert Langer and Stephen Berenson will retire from the Board on August 5, 2024.
• Both retiring directors will provide consulting services to the company through November 1, 2026.
• David Rubenstein will also join the Audit Committee, replacing Stephen Berenson.
• The size of the Board will be fixed at eight directors following these changes.
• Mr. Rubenstein will receive compensation as outlined in the company's Non-Employee Director Compensation Policy.
• The company is continuing to recruit directors with scientific and innovation experience.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment with the addition of a high-profile board member and the planned transition of existing members to advisory roles. There are no indications of negative issues, but the loss of two long-term board members is a minor concern.

Positives

• David Rubenstein brings extensive experience in investing and growing businesses across various industries.
• Mr. Rubenstein's global policy expertise is expected to benefit Moderna's global growth strategy.
• The continued advisory services of Robert Langer and Stephen Berenson will provide valuable insights to the company.
• The appointment of Mr. Rubenstein is seen as a positive step as Moderna scales efficiently and reaches new markets.

Negatives

• The departure of Robert Langer, a co-founder, and Stephen Berenson, who served since before the IPO, may represent a loss of institutional knowledge.
• The company will need to recruit a new director with scientific and innovation experience to replace Dr. Langer.

Risks

• The company acknowledges that forward-looking statements are subject to risks and uncertainties.
• The company's future development could be impacted by factors beyond its control.
• The company's risk factors are detailed in its annual report on Form 10-K and subsequent filings.

Future Outlook

Moderna aims to continue its growth as a commercial company with global reach, leveraging the expertise of its new board member and continuing to develop mRNA medicines.

Management Comments

• Noubar Afeyan stated that David Rubenstein brings a rich depth of experience and is a respected voice on policy and international affairs.
• David M. Rubenstein said he is honored to join Moderna and contribute to its success.
• Stéphane Bancel believes David Rubenstein is the ideal partner to help guide Moderna's growth.
• Robert Langer stated that now is the right time for him to step down after many years of service.
• Stephen Berenson expressed pride in the company's progress and his service to the company and its shareholders.

Industry Context

The appointment of a high-profile figure like David Rubenstein, with experience in private equity and global policy, suggests Moderna is focusing on strategic growth and global expansion. This move aligns with the trend of biotech companies seeking diverse expertise on their boards to navigate complex market dynamics.

Comparison to Industry Standards

• The appointment of a director with significant financial and policy experience is a common practice among large biotech companies, similar to how companies like Amgen and Gilead Sciences have structured their boards.
• The transition of board members to advisory roles is also a standard practice, allowing companies to retain valuable expertise, similar to how companies like Biogen have managed board transitions.
• The focus on recruiting directors with scientific and innovation experience is consistent with the needs of a research-driven company like Moderna, similar to how companies like Regeneron prioritize scientific expertise on their boards.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of David Rubenstein positively due to his extensive experience.
• Employees may be impacted by the changes in the board of directors.
• The company's customers and partners may see the changes as a sign of continued growth and stability.

Next Steps

• David Rubenstein will join the Board and Audit Committee on August 5, 2024.
• Robert Langer and Stephen Berenson will begin their consulting roles on August 5, 2024.
• Moderna will continue its director recruitment efforts focusing on individuals with scientific and innovation experience.

Key Dates

Keywords

Board of Directors, David Rubenstein, Robert Langer, Stephen Berenson, Corporate Governance, Audit Committee, Director Appointment, Director Resignation, mRNA Medicine, Biotechnology